

Formulary changes announced

Third Quarter 2024

Quarterly changes to Independent Health drug formularies are summarized below and are currently in effect unless otherwise noted.

Abbreviations used throughout

AL: age limit	LA: limited access (only available at certain pharmacies)	PB/PG: preferred brand/generic
BvD: prior authorization is limited to a check to see whether being billed Part B or Part D	lot: lotion	QL: quantity limit
cap: capsule	MDI: metered-dose inhaler/aerosol	SC: subcutaneous
CHP: Child Health Plus (Medicare)	NF: non-formulary	SL: sublingual
cr: cream	NPB/NPG: non-preferred brand/generic	sol: solution
DF: drug formulary	ODT: orally-disintegrating tablet	SP: specialty pharmacy
IM: intramuscular	oint: ointment	ST: step therapy required
inj: injection	ophth: ophthalmic	supp: suppository
IV: intravenous	PA: prior authorization required	susp: suspension
		T (before a number): tier
		tab: tablet

New drugs reviewed

Drug name (generic name)	SP	LA	DF1, FEHB, Pharmacy Benefit Dimensions	DF2, DF3, Essential	CHP	Medicare
Ahzantive (afibercept-mrbb)			Medical PA w/ ST (TBD)	Medical PA w/ ST (TBD)	Medical PA w/ ST (TBD)	Medical PA w/ ST (TBD)
Bkemv (eculizumab-aeeb)			Medical PA	Medical PA	Medical PA	Medical PA
Capvaxive (pneumococcal 21-valent conjugate vaccine)			Medical	Medical	Medical	Medical
Chewtadzy (tadalafil chewable tab)			NF	NF	NF	NF
Epysqli (eculizumab-aagh)			Medical PA	Medical PA	Medical PA	Medical PA
Erzofri (paliperidone palmitate)	X		Medical PA w/ ST (TBD)	Medical PA w/ ST (TBD)	Medical PA w/ ST (TBD)	NPB PA
Femlyv (norethindrone/ethinyl estradiol ODT)			NF	NF	NF	NF
Iqirvo (elafibranor)	X	X	NPB PA	NPB PA	NF	NPB PA
Kisunla (donanemab-azbt)			NF PA	NF PA	NF PA	Coverage to follow CMS determination
Leqselvi (deuruxolitinib)			NF	NF	Block (cosmetic)	NF
mRESVIA (respiratory syncytial virus vaccine)			Medical AL	Medical AL	Medical AL	PB AL
Nypozi (filgrastim-txid)			Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST
Ohtuvayre (ensifentrine)	X	X	NF PA	NF PA	NF	NPB PA
Onyda XR (clonidine ER susp)			NF	NF	NF	NF
PiaSky (crovalimab-akkz)			Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST
Pyzchiva (ustekinumab-ttwe)			NF	NF	NF	NF
Rytelo (imetelstat)			Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST
Sofdra (sofpironium)			NF	NF	NF	NF
Tecelra (afamitresgene autoleucel)			Medical PA	Medical PA	Medical PA	Medical PA
Tepylute (thiotepa)			Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST
Tezruly (terazosin)			NF	NF	NF	NF
Vigafyde (vigabatrin)			NF	NF	NF	NF
Voquezna (vonoprazan)			NPB PA w/ST	NPB PA w/ST	NF	NPB PA w/ST
Voranigo (vorasidenib)	X		NPB PA	NPB PA	NF	NPB PA
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)			Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST
Yimmugo (immune globulin intravenous, human-dira)			Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST	Medical PA w/ ST
Zituvimet XR (sitagliptin/metformin)			NF	NF	NF	NF
Zoryve (roflumilast)			NF	NF	NF	NF
Zunveyl (benzgalantamine)			NF	NF	NF	NF

New generic placements

Drug name (generic name)	DF1, FEHB, Pharmacy Benefit Dimensions	DF2, DF3, Essential	CHP	Medicare
Ala-Scalp (hydrocortisone lotion)	NF	NF	NF	NF/T3
Corlanor (ivabradine tab)	T3 PA	T3 PA	NF	T4 PA/T1 PA
Emflaza (deflazacort oral susp)	T3 PA/T5 PA	T3 PA	T1 PA	NF/NF
Endari (L-glutamine)	NF	NF	NF	T5 PA/T1 PA
Radicava (edaravone IV soln)	MEDICAL, PA	MEDICAL, PA	MEDICAL, PA	MEDICAL, PA
Victoza (authorized generic only)	T2	T2	T2	T3 ST/T2 ST

Other formulary changes

Drug name (generic name)	Applicable formularies	Changes
dihydroergotamine SC	Commercial	T2 to T3 effective 1/1/25
Migergot (ergotamine/cafeine)	DF1/PBD/FEHB	Add QL 12 effective 1/1/25
Reyvow (lasmiditan)	Commercial	NF for DF1/PBD/FEHB T3 DF2/DF3/Essential effective 1/1/25
Zembrace (sumatriptan)	Commercial	Add PA and QL 4 effective 1/1/25
Intrrosa (prasterone)	DF1/PBD/FEHB	Add to T3 effective 1/1/25
Edex (alprostadil)	DF1/PBD/FEHB	T2 to T3 effective 1/1/25
Praluent (alirocumab)	All formularies	NF
Sildenafil	DF1/DF2/DF3/PBD/FEHB	Increase QL to #10/30 effective 1/1/25

Coverage changes due to new indications

Drug name (generic name)	New indication	Changes
Arexvy (RSV vaccine, adjuvanted)	50-59 years of age in high risk individuals	AL changes
Augtyro (reprectinib)	NTRK gene fusion-positive solid tumors	PA policy changes
Blinicyto (blinatumomab)	CD19+ PH- B-cell precursor ALL in consolidation phase	PA policy changes
Breyanzi (lisocabtagene maraleucel)	Mantle cell lymphoma	PA policy changes
Darzalex Faspro (daratumumab hyaluronidase-fihj)	MM w/ other agents for induction & consolidation in newly diagnosed patients eligible for autologous HSCT	PA policy changes
Elevidys (delandistrogene moxeparvovec-rokl)	Removed upper AL on indication for DMD	No changes (blocked-efficacy)
Epkinly (epcoritamab-bysp)	r/r follicular lymphoma after 2+ lines systemic therapy	PA policy changes
Farxiga (daagliflozin)	T2DM down to 10 years of age	AL changes
Imfinzi (durvalumab)	dMMR endometrial Ca after carboplatin/paclitaxel	PA policy changes
Jemperli (dostarlimab-gxly)	endometrial Ca with carboplatin/paclitaxel	PA policy changes
Kevzara (sarilumab)	pJIA in pediatric patients ≥63kg	PA policy changes
Keytruda (pembrolizumab)	endometrial Ca after carboplatin/paclitaxel	PA policy changes
Kisqali (ribociclib)	Hr+, HER2- breast cancer in pre/perimenopausal women	PA policy changes
Krazati (adagrasib)	KRAS G12C-mutated colorectal Ca w/ cetuximab	PA policy changes
Livmarli (maralixibat)	lower AL for cholestatic pruritus down to 12 months of age	PA policy changes
Motpoly XR (lacosamide)	adjunctive for tonic-clonic seizures in patients ≥50kg	No changes (blocked-efficacy)
Palforzia (peanut allergen powder-dnfp)	lower AL down to 1 year of age	PA policy changes
Retevmo (selpercatinib)	RET+ solid tumors, thyroid Ca, medullary thyroid Ca all down to 2 years of age	PA policy changes
Skyrizi (risankizumab-rzaa)	ulcerative colitis in adults	PA policy changes
Velphoro (sucroferric oxyhydroxide)	lower AL down to 9 years of age	AL changes
Wakix (pitolisant)	EDS in pts w/ narcolepsy lower AL down to 6 years of age	PA policy changes
Xembify (SCIG, human-klhw)	treatment-naïve w/ primary humoral immunodeficiencies	PA policy changes
Xeomin (incobotulinumtoxinA)	reduces glabellar line, horizontal forehead lines, lateral canthal lines	Block indications-cosmetic
Xigduo XR (dapagliflozin/metformin)	T2DM down to 10 years of age	AL changes

Formulary changes announced for 2025

Approved in the August 2024 P&T meeting.

Abbreviations used throughout

AL: age limit	LA: limited access (only available at certain pharmacies)	PB/PG: preferred brand/generic
BvD: prior authorization is limited to a check to see whether being billed Part B or Part D	lot: lotion	QL: quantity limit
cap: capsule	MDI: metered-dose inhaler/aerosol	SC: subcutaneous
CHP: Child Health Plus (Medicare)	NF: non-formulary	SL: sublingual
cr: cream	NPB/NPG: non-preferred brand/generic	sol: solution
DF: drug formulary	ODT: orally-disintegrating tablet	SP: specialty pharmacy
IM: intramuscular	oint: ointment	ST: step therapy required
inj: injection	ophth: ophthalmic	supp: suppository
IV: intravenous	PA: prior authorization required	susp: suspension
		T (before a number): tier
		tab: tablet

2025 drug removals – products that are obsolete/no longer manufactured/ gone generic are not included

Actemra	Epsolay	Plegridy
Airsupra	estazolam	Procysbi
Altabax	Filsuvez	Prolensa
amoxicillin/clavulanate ER	Gralise	Rasuvo
Amvuttra	Harvoni	Rayaldee
Androderm	Hizentra	Rebif
Aranesp	Ilevro	Santyl
Asmanex	Ingrezza	Serostim
azathioprine 75 mg, 100 mg	Jynarque	Simponi
Azelex 20% cream	Kineret	Sogroya
Bafiertam	Lotemax ophthalmic ointment, 0.38% gel	Sovaldi
Binosto	Lupkynis	Symproic
bromfenac 0.07% ophthalmic solution	Mavenclad	Synarel
bromocriptine 5 mg	Migergot	Tarpeyo
Bryhali	Neulasta/Neulasta Onpro	tobramycin 300mg/4mL nebulizer soln
Camcevi	Nivestym	topiramate ER sprinkle cap
carvedilol ER tabs (remains on C-SNP)	Nucynta ER	Tremfya
cimetidine oral solution	Nymalize	tretinoin 0.05% gel, microsphere gel
Cimzia	Ocaliva	Upravi
Clarinex-D 12-hour	Orladeyo	Veltassa
Clenpiq	Oxtellar XR	Victoza
Cuvitru	oxycodone ER tab	Vistogard
Cycloset	Oxycontin	Vumerity
Egrifta SV	oxymorphone ER tab	Zegalogue
Enspryng	Pancreaze	Zeposia
Epclusa	Pertzye	Zerbaxa

2025 negative changes

Advair HFA add QL (reduce waste)	Farxiga bump to T3 on C-SNP (cost-effectiveness), 5 mg tab add QL (reduce waste)	Relistor add PA (cost-effectiveness)
----------------------------------	--	--------------------------------------

amoxapine tab bump to T3 (cost-effectiveness)	Fetzima add QL (reduce waste)	Ridaura bump to T5 (cost over SP threshold)
Arcalyst bump to T5 (cost over SP threshold)	fingolimod bump to T3 (cost-effectiveness)	risperidone ODT bump to T3 (cost-effectiveness), add QL (reduce waste)
asenapine SL tab add QL (reduce waste)	fluticasone HFA add QL (reduce waste)	rivastigmine patch bump to T3 (cost-effectiveness)
Atrovent inhaler bump to T4 (therapeutics)	fluticasone/salmeterol add QL (reduce waste)	ropinirole ER bump to T3 (cost-effectiveness), add QL (reduce waste)
betaine powder bump to T5 (cost over SP threshold)	fluvastatin bump to T3 (cost-effectiveness)	rufinamide 400 mg tab bump to T5 (cost over SP threshold)
Breztri add QL (reduce waste)	fosfomycin add QL (reduce waste)	Rybelsus bump to T3 on C-SNP (cost-effectiveness) change ST to PA (prevent off-label utilization), add QL to 3 mg tab (therapeutics)
Briviact add QL (reduce waste)	gabapentin oral sol bump to T3 (cost-effectiveness)	Rykindo add PA w/embedded ST (cost-effectiveness)
budesonide 9 mg ER tab bump to T5 (cost over SP threshold)	galantamine ER add QL (reduce waste)	Savella add QL (reduce waste)
buprenorphine patch bump to T3 (cost-effectiveness)	Gengraf solution bump to T3 (cost-effectiveness)	scopolamine patch bump to T3 (cost-effectiveness)
calcipotriene ointment bump to T3 (cost-effectiveness)	Glyxambi bump to T3 on C-SNP (cost-effectiveness)	Secuado add PA (contracting)
carbamazepine oral suspension and ER capsules bump to T3 (cost-effectiveness)	icosapent ethyl bump to T3 (cost-effectiveness)	sildenafil oral susp bump to T5 (cost over SP threshold)
cefadroxil 1 g tab bump to T3 (cost-effectiveness)	imatinib bump to T3 (cost-effectiveness)	sirolimus tabs bump to T4 (cost-effectiveness)
cefixime oral susp bump to T3 (cost-effectiveness)	Intelence bump to T4 (cost-effectiveness)	sodium phenylbutyrate powder bump to T5 (cost over SP threshold)
chlorpromazine tab bump to T4 (cost-effectiveness)	Isturisa 1 mg add QL (reduce waste)	Soliqua add QL (reduce waste)
ciprofloxacin/dexamethasone otic bump to T3 (cost-effectiveness)	Jardiance bump to T3 on C-SNP (cost-effectiveness), 10 mg tab add QL (reduce waste)	Spiriva add QL (reduce waste)
clarithromycin oral susp bump to T3 (cost-effectiveness)	Jentaduetto/Jentaduetto XR bump to T3 on C-SNP (cost-effectiveness)	Stiolto add QL (reduce waste)
Climara Pro add QL (reduce waste)	lacosamide oral sol bump to T4 (cost-effectiveness)	Striverdi QL (reduce waste)
clomipramine bump to T4 (cost-effectiveness)	Lagevrio bump to T3 (cost-effectiveness)	SymlinPen bump to T5 (cost over SP threshold)
clotrimazole/betamethasone lotion bump to T3 (cost-effectiveness)	lamotrigine ER tab bump to T4 (cost-effectiveness)	Synjardy/Synjardy XR bump to T3 on C-SNP (cost-effectiveness)

colestipol packets bump to T3 (cost-effectiveness)	levalbuterol HFA bump to T3 (cost-effectiveness)	telmisartan-amlodipine bump to T3 (cost-effectiveness)
CombiPatch add QL (reduce waste)	linezolid tab, IV sol bump to T4 (cost-effectiveness)	teriflunomide bump to T3 (cost-effectiveness), add QL (reduce waste)
cromolyn nebulizer sol bump to T3 (cost-effectiveness)	megestrol 625 mg/5 mL oral susp bump to T4 (cost-effectiveness)	testosterone 1% gel bump to T4 (cost-effectiveness)
cyclobenzaprine 7.5 mg tab bump to T3 (cost-effectiveness)	Menostar add QL (reduce waste)	tiagabine bump to T4 (cost-effectiveness), add QL (reduce waste)
cyclosporin modified oral sol bump to T3 (cost-effectiveness)	meropenem IV bump to T3 (cost-effectiveness)	tolvaptan add QL (reduce waste)
dalfampridine 10 mg bump to T3 (cost-effectiveness)	methazolamide bump to T3 (cost-effectiveness)	Tradjenta bump to T3 on C-SNP (cost-effectiveness)
desmopressin refrigerated nasal solution bump to T3 (cost-effectiveness)	metronidazole 0.75% lotion bump to T3 (cost-effectiveness)	tramadol ER tab regular bump to T3 (cost-effectiveness)
desonide 0.05% lotion bump to T3 (cost-effectiveness)	minocycline tabs bump to T3 (cost-effectiveness)	tramadol ER tab biphasic bump to T3 (cost-effectiveness), remove ST (cost-effectiveness)
desvenlafaxine ER (Khedezla generic) bump to T4 (cost-effectiveness)	morphine ER caps bump to T3 (cost-effectiveness)	travoprost bump to T3 (cost-effectiveness)
dicyclomine oral sol bump to T4 (cost-effectiveness)	morphine ER bead caps bump to T4 (cost-effectiveness)	tretinoin 0.01, 0.025% gel, 0.01, 0.025, 0.05% cream bump to T3 (cost-effectiveness)
doxercalciferol capsules bump to T4 (cost-effectiveness)	Mounjaro bump to T3 on C-SNP (cost-effectiveness) change ST to PA (prevent off-label utilization), add QL (reduce waste)	trospium ER bump to T3 (cost-effectiveness)
dronabinol bump to T4 (cost-effectiveness)	nitroglycerin SL spray bump to T3 (cost-effectiveness)	Trulicity bump to T3 on C-SNP (cost-effectiveness) change ST to PA (prevent off-label utilization), add QL (reduce waste)
dutasteride-tamsulosin bump to T4 (cost-effectiveness)	Ozempic bump to T3 on C-SNP (cost-effectiveness) change ST to PA (prevent off-label utilization), add QL (reduce waste)	Unithroid bump to T4 (cost-effectiveness)
enoxaparin bump to T3 (cost-effectiveness)	paliperidone bump to T3 (cost-effectiveness), add QL to 1.5 and 3 mg tab (reduce waste)	Uzedy add PA w/embedded ST (cost-effectiveness)
Entresto add QL (reduce waste)	Paxlovid bump to T3 (cost-effectiveness)	valganciclovir tab bump to T3 (cost-effectiveness)
epinephrine auto-injectors bump to T3 (cost-effectiveness), add QL (reduce waste)	pentazocine/naloxone bump to T3 (cost-effectiveness)	valganciclovir oral susp bump to T5 (cost over SP threshold)
Eraxis bump to T5 (cost over SP threshold)	Perseris add PA w/embedded ST (cost-effectiveness)	Vowst add QL (reduce waste)
erlotinib bump to T3 (cost-effectiveness), remove PA (therapeutics)	pirfenidone bump to T5 (cost over SP threshold)	Xifaxan 550 mg tab add PA (reduce waste)
estradiol patch add QL (reduce waste)	pregabalin oral sol bump to T3 (cost-effectiveness)	Xigduo XR bump to T3 on C-SNP (cost-effectiveness)
Fanapt add PA (contracting)	Prosol 20% IV sol bump to T4 (cost-effectiveness)	Zontivity change PA from new starts to all (therapeutics)

2025 positive changes and drug adds		
abiraterone 250 mg tab remove PA	mesalamine 500 mg ER cap (generic Pentasa) drop to T4	risperidone 25 mg IM drop to T2
acitretin drop to T3	micafungin IV drop to T4	tadalafil 2.5 mg and 5 mg to T2 w/PA (therapeutics)
ampicillin-sulbactam drop to T2	Mirena 52 mg IUD (therapeutics)	tetrabenazine remove PA
atovaquone oral susp drop to T4	Movantik drop to T3	timolol/dorzolamide preservative-free drop to T3
deferasirox remove PA	Nexletol drop to T3	Triumeq soluble tab drop to T4
Depo-SubQ Provera 104 drop to T3	Nexlizet drop to T3	Vemlidy remove PA
difluprednate ophthalmic emulsion drop to T2	Nexplanon 86 mg SC implant (therapeutics)	vilazodone drop to T2
Gleostine 10 mg tab drop to T4	Nitro-Bid drop to T3	Vraylar remove PA
Impavido (therapeutics)	pitavastatin drop to T3	Xdemvy (therapeutics)
lubiprostone drop to T3		